$37.02
0[0.00%]
Last update: 4:03PM Get Real Time Here
Celldex Therapeutics
(NASDAQ:CLDX)Latest News for Celldex Therapeutics Stock (NASDAQ:CLDX)
Celldex Therapeutics Stock (NASDAQ: CLDX)
Categories: All
Wednesday, April 17, 2024
Friday, March 22, 2024
Friday, March 15, 2024
Friday, March 01, 2024
Wednesday, February 28, 2024
Tuesday, February 27, 2024
Monday, February 26, 2024
- Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Feb 26, 2024, 1:57PM
- Celldex Therapeutics shares are trading higher after the company reported better-than-expected Q4 revenue results.Benzinga Newsdesk - Feb 26, 2024, 12:10PM
- Celldex Therapeutics: Q4 Earnings InsightsBenzinga Insights - Feb 26, 2024, 11:55AM
- Celldex Therapeutics Entered Deal To Sell Shares Of Up To $300M Common Stock Offering From Time To TimeBenzinga Newsdesk - Feb 26, 2024, 9:58AM
- Celldex Therapeutics Q4 EPS $(0.83) Misses $(0.74) Estimate, Sales $4.13M Beat $840.00K EstimateBenzinga Newsdesk - Feb 26, 2024, 7:05AM
Saturday, February 24, 2024
Monday, February 05, 2024
Wednesday, December 20, 2023
- Forecasting The Future: 5 Analyst Projections For Celldex TherapeuticsBenzinga Insights - Dec 20, 2023, 2:00PM
- TD Cowen Initiates Coverage On Celldex Therapeutics with Outperform RatingBenzinga Newsdesk - Dec 20, 2023, 8:34AM
- Top 4 Health Care Stocks That May Crash This MonthAvi Kapoor - Dec 20, 2023, 8:31AM
Friday, November 10, 2023
Wednesday, November 08, 2023
- Why Celldex Therapeutics (CLDX) Stock Is Getting HammeredHenry Khederian - Nov 8, 2023, 2:58PM
- Celldex Therapeutics shares are trading lower after the company announced a proposed public offering of 7.425 million shares at $27 per share.Benzinga Newsdesk - Nov 8, 2023, 1:06PM
- Celldex Therapeutics Prices Public Offering of 7.425M Common Shares At $27/ShareBenzinga Newsdesk - Nov 8, 2023, 2:51AM
Tuesday, November 07, 2023
Monday, November 06, 2023
- Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Nov 6, 2023, 1:36PM
- HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $80Benzinga Newsdesk - Nov 6, 2023, 11:09AM
- Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?Vandana Singh - Nov 6, 2023, 10:27AM
- Market-Moving News for November 6thBenzinga Newsdesk - Nov 6, 2023, 8:55AM
- Celldex Therapeutics shares are trading higher after the company announced data from its phase 2 trial treating urticaria refractory.Luke J Jacobi - Nov 6, 2023, 8:25AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Nov 6, 2023, 8:06AM
- Celldex Therapeutics' Topline Results From Its Phase 2 Trial Of Barzolvolimab For Moderate To Severe Chronic Spontaneous Urticaria Refractory To Antihistamines Met Primary Endpoint Showing Decrease In Disease Activity Across Multiple DosesBenzinga Newsdesk - Nov 6, 2023, 6:43AM
- Reported Earlier, Celldex Therapeutics Announces Data From Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction In Itch And Skin Clearing With Single Dose 3.0 Mg/Kg BarzolvolimabBenzinga Newsdesk - Nov 6, 2023, 1:26AM
Friday, November 03, 2023
- Celldex Therapeutics Inc Files For Mixed Shelf; Size Not DisclosedBenzinga Newsdesk - Nov 3, 2023, 4:09PM
- Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $52Benzinga Newsdesk - Nov 3, 2023, 12:49PM
- Celldex Therapeutics shares are trading higher after the company reported better-than-expected Q3 revenue results.Benzinga Newsdesk - Nov 3, 2023, 12:37PM